Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Payables (2020 - 2025)

Historic Payables for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $6.4 million.

  • TScan Therapeutics' Payables rose 7419.8% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 7419.8%. This contributed to the annual value of $4.3 million for FY2024, which is 8020.22% up from last year.
  • According to the latest figures from Q3 2025, TScan Therapeutics' Payables is $6.4 million, which was up 7419.8% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Payables registered a high of $6.4 million during Q3 2025, and its lowest value of $1.8 million during Q4 2021.
  • In the last 5 years, TScan Therapeutics' Payables had a median value of $3.2 million in 2023 and averaged $3.5 million.
  • As far as peak fluctuations go, TScan Therapeutics' Payables tumbled by 4660.88% in 2022, and later skyrocketed by 13391.43% in 2025.
  • Over the past 5 years, TScan Therapeutics' Payables (Quarter) stood at $1.8 million in 2021, then surged by 64.99% to $2.9 million in 2022, then fell by 18.48% to $2.4 million in 2023, then skyrocketed by 80.2% to $4.3 million in 2024, then soared by 48.5% to $6.4 million in 2025.
  • Its Payables was $6.4 million in Q3 2025, compared to $4.5 million in Q2 2025 and $5.0 million in Q1 2025.